Iron overload in myelodysplastic syndromes
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Myelodysplastic syndromes (MDS) are a group of disorders characterized by ineffective hematopoiesis that leads to peripheral cytopenias. Iron overload results from high transfusion requirements and retrospective studies have shown it to be associated with relatively poor survival in a subset of the low risk patients. Recent discoveries have led to the identification of hepcidin as a key regulator of iron metabolism and to the association of non-transferrin bound iron moieties, such as labile plasma iron, with the end organ damage in iron overload states. Currently, there is limited data in evaluating the role of iron chelators in MDS and data from studies in Thalassemia and hemachromostosis have been used to predict ferritin levels above 1000 - 2500 ng/mL and history of 20 blood transfusions as clinical end points for considering iron chelation in MDS. Deferoxamine and deferasirox, the two iron chelators approved for use in the US, have shown efficacy in reducing iron overload in MDS in retrospective studies are now being evaluated for effects on overall survival in prospective studies. On the basis of retrospective data, it is reasonable to offer iron chelation to the lower risk MDS patients requiring frequent transfusions, while monitoring for specific adverse affects in patients on treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 1×
“Hepcidin, a peptide made predominantly in the liver, is the principal regulator of systemic iron homeostasis [10].”
BackgroundLenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · cited 1×
“In 1999, the World Health Organization (WHO) proposed a new classification of MDS (Table II) [7,8].”
BackgroundThe iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275 · cited 1×
“Ferroportin (Fpn/IREG-1/ Slc40a1/MTP-1) is a major cellular exporter of iron in mammals, highly expressed in cells that export iron (macrophages, hepatocytes, duodenal enterocytes, and placental cells) [13].”
BackgroundNicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
Severe iron deficiency anemia in transgenic mice expressing liver hepcidin
Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C., Grandchamp, B., Sirito, M., Sawadogo, M., Kahn, A., & Vaulont, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072632499 · Cited by 880
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756 · cited 1×
“The simultaneous decrease in hepcidin levels is adaptive, enabling increased iron absorption from the diet and iron mobilization from the macrophages and hepatocytes, making more iron available for erythrocyte production (Figure 2) [16].”
BackgroundLabile plasma iron in iron overload: redox activity and susceptibility to chelation
Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., & Cabantchik, Z. I. (2003) · Blood · doi:10.1182/blood-2003-03-0807 · Cited by 475
Hepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445 · cited 1×
“Measurement of urinary hepcidin in these patients indicates that hepcidin levels are insufficiently increased relative to systemic iron overload as reflected by the patients’ elevated serum ferritin levels [17].”
BackgroundArmand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Soiffer, R. J., & Antin, J. H. (2007) · Blood · doi:10.1182/blood-2006-10-054924 · Cited by 426
Redox active plasma iron in C282Y/C282Y hemochromatosis
Le Lan, C., Loréal, O., Cohen, T., Ropert, M., Glickstein, H., Lainé, F., Pouchard, M., Deugnier, Y., Le Treut, A., Breuer, W., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3468 · Cited by 151
Cited by
Non-transferrin bound iron: a key role in iron overload and iron toxicity
Brissot, P., Ropert, M., Le Lan, C., & Loréal, O. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.014 · Cited by 654
Iron Overload in Human Disease
Fleming, R. E., & Ponka, P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1004967 · Cited by 587
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Kikuchi, S., Kobune, M., Iyama, S., Sato, T., Murase, K., Kawano, Y., Takada, K., Ono, K., Kaneko, Y., Miyanishi, K., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.006 · Cited by 56
Metadata
- Authors
- Mahesh, S., Ginzburg, Y., & Verma, A.
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 49
- Issue
- 3
- Pages
- 427-438
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2087503863
- Cited by
- 41
- References
- 11
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Iron overload in myelodysplastic syndromes. https://app.cochat.ai/papers/10.1080/10428190701843221
- The paper
- Mahesh, S., Ginzburg, Y., & Verma, A. (2008). Iron overload in myelodysplastic syndromes. Leukemia & Lymphoma. https://doi.org/10.1080/10428190701843221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.